Protocols Used in Chemotherapy Treatment of Neonates and Infants

  • Carolina Witchmichen Penteado Schmidt


The protocols cited here are provided for quick reference, being necessary a full study of each complete protocol before prescribing; the protocols cited here are referenced in the final section of this book. Protocols may vary according to each institution. It is important to know every drug used in the protocol, to take the necessary care, and to perform the necessary examinations to avoid collateral effects and toxicity. The protocols for neonates and infants should be prescribed by an experienced oncopediatric physician—or under his/her constant supervision if they are prescribed by an oncopediatric physician who is not so accustomed to treating neonates and infants—and should be analyzed and handled by a pharmacist with extensive experience in the oncopediatric area. The protocols should also be administered by a nurse who is experienced in the areas of neonatology and oncology. It is essential that the protocols are devised by the institution before they need to be used, so the professionals have time to study and standardize drug brands, procedures for care, and other needs.


  1. 30.
    Pieters R, Schrappe M, Valsecchi MG, Biondi A, et al. INTERFANT-06: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia. Stichting Kinderoncologie Nederland. 2016. Accessed 13 Jan 2017.
  2. 31.
    Interfant 2006. Stichting Kinderoncologie Nederland. Accessed 13 Jan 2017.
  3. 34.
    Munõz L, Nomdedéu JF, Villamor N, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Lekemia. 2003;17:76–82.CrossRefGoogle Scholar
  4. 32.
    Grümayer ER, Schmidmeyer W, Panzer S, Gadner H. Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemia. Blut. 1986;53(4):309–14.CrossRefGoogle Scholar
  5. 37.
    Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477–89.CrossRefGoogle Scholar
  6. 1.
    Schmidt CWP, Menezes FG. Drug therapy and interactions in pediatric oncology: a pocket guide. Switzerland: Springer; 2017.CrossRefGoogle Scholar
  7. 36.
    Busato M, Ceresér KMM, Onsten TGH, Feijó CS, Schostack N. Protocolo mais utilizado no tratamento da leucemia linfocítica aguda na infância em hospitais de Porto Alegre. Ped Mod. 2003;39:432–45.Google Scholar
  8. 45.
    Masetti R, Vendemini F, Zama D, Biagi C, Pession A, Locatelli F. Acute myeloid leukemia in infants: biology and treatment. Front Pediatr. 2015;3:37.CrossRefGoogle Scholar
  9. 46.
    Pession A, Rondelli R, Basso G, et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19(12):2043–53.CrossRefGoogle Scholar
  10. 38.
    Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. Pediatric Cancer. Accessed 13 Jul 2017.
  11. 68.
    Veal GJ, Errington J, Sastry J, et al. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol. 2016;77:685–92. CrossRefGoogle Scholar
  12. 71.
    Veal GJ, Errington J, Hayden J, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51(14):2022–30.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Carolina Witchmichen Penteado Schmidt
    • 1
  1. 1.CuritibaBrazil

Personalised recommendations